These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31531359)

  • 1. Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945.
    Lee JY; Yun JS; Kim WK; Chun HS; Jin H; Cho S; Chang JH
    Biomed Res Int; 2019; 2019():6125068. PubMed ID: 31531359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
    Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
    Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel function of CX-4945 as a splicing regulator.
    Kim H; Choi K; Kang H; Lee SY; Chi SW; Lee MS; Song J; Im D; Choi Y; Cho S
    PLoS One; 2014; 9(4):e94978. PubMed ID: 24743259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGC-CLK-1: A chemical probe for the Cdc2-like kinases CLK1, CLK2, and CLK4.
    Tiek D; Wells CI; Schröder M; Song X; Alamillo-Ferrer C; Goenka A; Iglesia R; Lu M; Hu B; Kwarcinski F; Sintha P; de Silva C; Hossain MA; Picado A; Zuercher W; Zutshi R; Knapp S; Riggins RB; Cheng SY; Drewry DH
    Curr Res Chem Biol; 2023; 3():. PubMed ID: 38009092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Cdc2-like Kinase 2 Inhibitors: Achievements and Future Directions.
    Qin Z; Qin L; Feng X; Li Z; Bian J
    J Med Chem; 2021 Sep; 64(18):13191-13211. PubMed ID: 34519506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.
    Fedorov O; Huber K; Eisenreich A; Filippakopoulos P; King O; Bullock AN; Szklarczyk D; Jensen LJ; Fabbro D; Trappe J; Rauch U; Bracher F; Knapp S
    Chem Biol; 2011 Jan; 18(1):67-76. PubMed ID: 21276940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation.
    Bullock AN; Das S; Debreczeni JE; Rellos P; Fedorov O; Niesen FH; Guo K; Papagrigoriou E; Amos AL; Cho S; Turk BE; Ghosh G; Knapp S
    Structure; 2009 Mar; 17(3):352-62. PubMed ID: 19278650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing.
    Araki S; Dairiki R; Nakayama Y; Murai A; Miyashita R; Iwatani M; Nomura T; Nakanishi O
    PLoS One; 2015; 10(1):e0116929. PubMed ID: 25581376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. X-ray Structures and Feasibility Assessment of CLK2 Inhibitors for Phelan-McDermid Syndrome.
    Kallen J; Bergsdorf C; Arnaud B; Bernhard M; Brichet M; Cobos-Correa A; Elhajouji A; Freuler F; Galimberti I; Guibourdenche C; Haenni S; Holzinger S; Hunziker J; Izaac A; Kaufmann M; Leder L; Martus HJ; von Matt P; Polyakov V; Roethlisberger P; Roma G; Stiefl N; Uteng M; Lerchner A
    ChemMedChem; 2018 Sep; 13(18):1997-2007. PubMed ID: 29985556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.
    Iwai K; Yaguchi M; Nishimura K; Yamamoto Y; Tamura T; Nakata D; Dairiki R; Kawakita Y; Mizojiri R; Ito Y; Asano M; Maezaki H; Nakayama Y; Kaishima M; Hayashi K; Teratani M; Miyakawa S; Iwatani M; Miyamoto M; Klein MG; Lane W; Snell G; Tjhen R; He X; Pulukuri S; Nomura T
    EMBO Mol Med; 2018 Jun; 10(6):. PubMed ID: 29769258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members.
    Prak K; Kriston-Vizi J; Chan AW; Luft C; Costa JR; Pengo N; Ketteler R
    Biochemistry; 2016 Jan; 55(3):608-17. PubMed ID: 26701387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opposing roles of CLK SR kinases in controlling HIV-1 gene expression and latency.
    Dahal S; Clayton K; Been T; Fernet-Brochu R; Ocando AV; Balachandran A; Poirier M; Maldonado RK; Shkreta L; Boligan KF; Guvenc F; Rahman F; Branch D; Bell B; Chabot B; Gray-Owen SD; Parent LJ; Cochrane A
    Retrovirology; 2022 Aug; 19(1):18. PubMed ID: 35986377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.
    Funnell T; Tasaki S; Oloumi A; Araki S; Kong E; Yap D; Nakayama Y; Hughes CS; Cheng SG; Tozaki H; Iwatani M; Sasaki S; Ohashi T; Miyazaki T; Morishita N; Morishita D; Ogasawara-Shimizu M; Ohori M; Nakao S; Karashima M; Sano M; Murai A; Nomura T; Uchiyama N; Kawamoto T; Hara R; Nakanishi O; Shumansky K; Rosner J; Wan A; McKinney S; Morin GB; Nakanishi A; Shah S; Toyoshiba H; Aparicio S
    Nat Commun; 2017 Feb; 8(1):7. PubMed ID: 28232751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Clk2 and Clk3 dual-specificity protein kinases regulate the intranuclear distribution of SR proteins and influence pre-mRNA splicing.
    Duncan PI; Stojdl DF; Marius RM; Scheit KH; Bell JC
    Exp Cell Res; 1998 Jun; 241(2):300-8. PubMed ID: 9637771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells.
    Bowler E; Porazinski S; Uzor S; Thibault P; Durand M; Lapointe E; Rouschop KMA; Hancock J; Wilson I; Ladomery M
    BMC Cancer; 2018 Apr; 18(1):355. PubMed ID: 29606096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype.
    Walter A; Chaikuad A; Helmer R; Loaëc N; Preu L; Ott I; Knapp S; Meijer L; Kunick C
    PLoS One; 2018; 13(5):e0196761. PubMed ID: 29723265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of influenza A virus mRNA splicing by CLK1.
    Artarini A; Meyer M; Shin YJ; Huber K; Hilz N; Bracher F; Eros D; Orfi L; Keri G; Goedert S; Neuenschwander M; von Kries J; Domovich-Eisenberg Y; Dekel N; Szabadkai I; Lebendiker M; Horváth Z; Danieli T; Livnah O; Moncorgé O; Frise R; Barclay W; Meyer TF; Karlas A
    Antiviral Res; 2019 Aug; 168():187-196. PubMed ID: 31176694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular Potency.
    ElHady AK; El-Gamil DS; Chen PJ; Hwang TL; Abadi AH; Abdel-Halim M; Engel M
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33668683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cellular localization of the murine serine/arginine-rich protein kinase CLK2 is regulated by serine 141 autophosphorylation.
    Nayler O; Schnorrer F; Stamm S; Ullrich A
    J Biol Chem; 1998 Dec; 273(51):34341-8. PubMed ID: 9852100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention.
    Uzor S; Zorzou P; Bowler E; Porazinski S; Wilson I; Ladomery M
    Gene; 2018 Sep; 670():46-54. PubMed ID: 29802995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.